How Much is Actavis Worth? A Lot More Than It is Now

JPmorgan’s Chris Schott and team think there is “compelling valuation upside” in Actavis’ (ACT) shares, especially following Teva Pharmaceutical’s (TEVA) big for Mylan (MYL). They explain why: Actavis Overall, Actavis remains our top pick, driven by a combination of strong organic growth (high single digit top-line/double digit EPS), a range of upside drivers to estimates (including [...]